Lv5
1150 积分 2024-07-23 加入
Interferons in health and disease
15天前
已完结
Efficacy, safety, and target engagement of dazukibart, an IFNβ specific monoclonal antibody, in adults with dermatomyositis: a multicentre, double-blind, randomised, placebo-controlled, phase 2 trial
18天前
已完结
Correlation of cutaneous disease activity with type 1 interferon gene signature and interferon β in dermatomyositis
18天前
已完结
A novel treatment for refractory dermatomyositis: A systematic review of anifrolumab and dermatomyositis
20天前
已完结
POS1033 EFFICAY AND SAFETY OF ANIFROLUMAB IN REFRACTORY DERMATOMYOSITIS. A CLINICAL EXPERIENCE
20天前
已关闭
2016 American College of Rheumatology/European League Against Rheumatism criteria for minimal, moderate, and major clinical response in adult dermatomyositis and polymyositis
20天前
已完结
Safety, Tolerability, and Pharmacokinetics of PF-06823859, an Anti–Interferon β Monoclonal Antibody: A Randomized, Phase I, Single- and Multiple-Ascending-Dose Study
22天前
已完结
Efficacy, safety, and target engagement of dazukibart, an IFNβ specific monoclonal antibody, in adults with dermatomyositis: a multicentre, double-blind, randomised, placebo-controlled, phase 2 trial
23天前
已完结
Efficacy and Safety of Obinutuzumab in Active Lupus Nephritis
26天前
已完结
皖公网安备34019202002308
